Summit continues to make strong progress with its utrophin modulation and C. difficile infection (CDI) programmes. Ezutromid is due to commence a PhaseOut DMD trial in Q2 with the first biopsy data in January 2017 and ridinilazole Phase III options are currently being evaluated for CDI. There is currently no cure for DMD, a fatal muscle wasting Orphan disease in the US and Europe, which affects around 1 in 3,500 male births, and unlike other approaches in development Summit’s utrophin modulation ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 2017 results
Summit continues to make strong progress with its utrophin modulation and C. difficile infection (CDI) programmes. Ezutromid is due to commence a PhaseOut DMD trial in Q2 with the first biopsy data in January 2017 and ridinilazole Phase III options are currently being evaluated for CDI. There is currently no cure for DMD, a fatal muscle wasting Orphan disease in the US and Europe, which affects around 1 in 3,500 male births, and unlike other approaches in development Summit’s utrophin modulation ....